Efficacy of Vitamin D compounds to modulate estrogen receptor negative breast cancer growth and invasion

Flanagan, Louise; Packman, Kathryn; Juba, Brian; O’Neill, Sharon; Tenniswood, Martin; Welsh, JoEllen

doi:10.1016/s0960-0760(03)00028-1

Cited by 82 publications

(67 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although power for these comparisons was low and results were not statistically significant, our findings suggested that 25(OH)D was inversely associated with risk of ERÀ/PRÀ negative tumors, but not with ER+/PR+ and ER+/PRÀ tumors. In vitro studies have suggested that the action of 1,25(OH) 2 D on breast tumors may be through pathways other than the disruption of estrogen signaling (32), and that cells derived from ERÀ tumors may undergo regression through apoptosis after exposure to 1,25(OH) 2 D. Further exploration of potential differences in the relationship between vitamin D metabolites and incidence of ERÀ breast tumors may be warranted.…”

Section: Discussionmentioning

confidence: 99%

Plasma 25-Hydroxyvitamin D and 1,25-Dihydroxyvitamin D and Risk of Breast Cancer

Bertone‐Johnson

Chen

Holick

et al. 2005

Cancer Epidemiology, Biomarkers &Amp; Prevention

340

261

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Plasma 25-Hydroxyvitamin D and 1,25-Dihydroxyvitamin D and Risk of Breast Cancer

Bertone‐Johnson

Chen

Holick

et al. 2005

Cancer Epidemiology, Biomarkers &Amp; Prevention

340

261

View full text Add to dashboard Cite

show abstract

“…[37][38][39] Yet responsiveness to the growth inhibitory effects of vitamin D in ER2 tumor cells have also been reported. 40,41 The observations on effect modification by receptor status of the tumor could have been a chance finding since the number of cases was very small, and test for heterogeneity in a case-only model was borderline significant only for PR status of the tumor.…”

Section: Discussionmentioning

confidence: 99%

Plasma 25‐hydroxyvitamin D and premenopausal breast cancer risk in a German case‐control study

Abbas

Chang‐Claude

Linseisen

2008

Intl Journal of Cancer

110

View full text Add to dashboard Cite

Laboratory and epidemiological data have linked vitamin D to breast cancer prevention. Beside dietary intake, endogenous production of vitamin D substantially contributes to a subject's vitamin D status. Most studies, however, have assessed dietary intake only. Although differential effects of vitamin D on premenopausal and postmenopausal breast cancer have been discussed, this is the first study to investigate the association of plasma 25-hydroxyvitamin D [25(OH)D], as indicator of the overall vitamin D status, with breast cancer risk with restriction to premenopausal women only. We used data of a population-based case-control study comprising 289 cases and 595 matched controls. Information on sociodemographic and breast cancer risk factors was collected by questionnaire and plasma 25(OH)D was measured by enzyme immunoassay. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated using conditional logistic regression. We observed a significant inverse association between breast cancer risk and plasma 25(OH)D concentrations. Compared with the lowest category (<30 nmol/L), the ORs (95% CI) for the upper categories [18][19][20] Few studies have assessed the relationship between serum or plasma 25(OH)D and breast cancer risk. [21][22][23][24][25] Of 2 small hospitalbased case-control studies in predominantly postmenopausal women, one study found a significantly inverse association 23 whereas the other study revealed no association between plasma 25(OH)D and breast cancer risk. 25 To date, 2 studies assessed the association of vitamin D metabolites with breast cancer risk with restriction to postmenopausal women only. 21,22 A study nested in the prostate, lung, colorectal and ovarian cancer screening trial reported no association between both higher plasma 25(OH)D and 1,25(OH) 2 D concentration and breast cancer risk. 22 However, a strong statistically significant inverse association between postmenopausal breast cancer risk and serum 25(OH)D was found in a large case-control study. 21 A case-control study nested in the Nurses' Health Study (NHS) is the only study that so far reported results stratified by menopausal status. 24 The authors reported a nonsignificant decrease in breast cancer risk with both higher plasma 25(OH)D and 1,25(OH) 2 D concentration for overall breast cancer risk. Stratification by menopausal status suggested an inverse association for postmenopausal women only, however power was low for their analysis in premenopausal women and risk estimates were not presented. As reviewed recently, prospective studies on dietary intake of vitamin D suggest a more pronounced effect for premenopausal breast cancer risk. 26 Furthermore, we recently reported a significant inverse association of dietary vitamin D with premenopausal breast cancer risk in the present study population. 13 To our knowledge, no study so far assessed the association of plasma 25(OH)D with restriction to premenopausal breast cancer only. Following our previous report on the association between postmenopausal breast canc...

show abstract

“…288,289 Moreover, it is now clear that some, though not all, of the cancers that arise from these epithelia continue to express both 1α-hydroxylase and the vitamin D receptor; thus, it may be feasible to beneficially modify the behavior of these cancers through vitamin D supplementation. [281][282][283]290 There is certainly no doubt that calcitriol, or its less calcemic synthetic analogs, can suppress the growth and spread in nude mice of many human tumors that express the vitamin D receptor [291][292][293] ; such tumors, which likewise express 1α-hydroxylase activity, may be susceptible to supplemental vitamin D as well. Moreover, activated macrophages that infiltrate tumors may serve as a paracrine source of calcitriol when vitamin D is supplemented.…”

Section: Ensuring Good Micronutrient Statusmentioning

confidence: 99%

Toward a Core Nutraceutical Program for Cancer Management

McCarty

Block

2006

Integr Cancer Ther

View full text Add to dashboard Cite

As previously suggested, it may be feasible to impede tumorevoked angiogenesis with a nutraceutical program composed of glycine, fish oil, epigallocatechin-3-gallate, selenium, and silymarin, complemented by a low-fat vegan diet, exercise training, and, if feasible, a salicylate and the drug tetrathiomolybdate. It is now proposed that the scope of this program be expanded to address additional common needs of cancer patients: blocking the process of metastasis; boosting the cytotoxic capacity of innate immune defenses (natural killer [NK] cells); preventing cachexia, thromboembolism, and tumor-induced osteolysis; and maintaining optimal micronutrient status. Modified citrus pectin, a galectin-3 antagonist, has impressive antimetastatic potential. Mushroom β-glucans and probiotic lactobacilli can amplify NK activity via stimulatory effects on macrophages. Selenium, β-carotene, and glutamine can also increase the number and/or cytotoxic activity of NK cells. Cachectic loss of muscle mass can be opposed by fish oil, glutamine, and β-hydroxy-β-methylbutyrate. Fish oil, policosanol, and vitamin D may have potential for control of osteolysis. High-dose aspirin or salicylates, by preventing NF-κB activation, can be expected to aid prevention of metastasis and cachexia while down-regulating osteolysis, but their impacts on innate immune defenses will not be entirely favorable. A nutritional insurance formula crafted for the special needs of cancer patients can be included in this regimen. To minimize patient inconvenience, this complex core nutraceutical program could be configured as an oil product, a powder, and a capsule product, with the nutritional insurance formula provided in tablets. It would be of interest to test this program in nude mouse xenograft models.

show abstract

Efficacy of Vitamin D compounds to modulate estrogen receptor negative breast cancer growth and invasion

Cited by 82 publications

References 27 publications

Plasma 25-Hydroxyvitamin D and 1,25-Dihydroxyvitamin D and Risk of Breast Cancer

Plasma 25-Hydroxyvitamin D and 1,25-Dihydroxyvitamin D and Risk of Breast Cancer

Plasma 25‐hydroxyvitamin D and premenopausal breast cancer risk in a German case‐control study

Toward a Core Nutraceutical Program for Cancer Management

Contact Info

Product

Resources

About